| 生物活性 | |||
|---|---|---|---|
| 靶点 |
|
||
| 描述 | Avitinib is an irreversible EGFR inhibitor selectively targeting mutated EGFR active and T790M mutations with IC50 value of 0.18nM against EGFR L858R/T790M double mutations, nearly 43-fold greater potency over wild-type EGFR (IC50=7.68nM), in the kinase enzymatic assay. AC0010 potently inhibited cellular EGFR-Tyr1068 phosphorylation with IC50 value of 4.4nM and 9.8nM in NCIH1975 cells and HCC827 cells, respectively, accompanied with inhibited phosphorylation of the downstream targets Akt and ERK1/2. In a xenograft model, oral administration of AC0010 at a daily dose of 500 mg/kg resulted in complete remission of tumors with EGFR-active and T790M mutations for over 143 days with no weight loss[2] | ||
| 作用机制 | Avitinib covalently modifies recombinant EGFR T790M mutation at the target cysteine 797 amino acid.[2] | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.05mL 0.41mL 0.21mL |
10.26mL 2.05mL 1.03mL |
20.51mL 4.10mL 2.05mL |
| 参考文献 |
|---|